Among these, SGLT2 inhibitors have shown remarkable efficacy in reducing MACE, including hospitalization for heart failure, atherosclerotic cardiovascular events, sudden cardiac death, and renal complications. The gene discussed is SLC5A2; the disease is heart failure.